Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Novel Bioluminescent Bioassays for the Discovery and Development of Molecular and Cellular T Cell-Redirecting Cancer Therapy

Part # PS368


Julia Gilden, Jamison Grailer, Michael Slater, Pete Stecha, Jim Hartnett, Dan Lazar, Frank Fan, Mei Cong and Zhijie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd., Madison WI 53711

This poster describes a platform of bioluminescent T Cell bioassays for the discovery and development of T Cell-redirecting cancer therapy:

TCRαβ-Deficient Reporter T Cells for Screening and Characterizing Antigen-Specific Therapeutic TCRs

  • TCRαβ-deficient reporter T Cells can prevent the recombination of endogenous and transgenic TCRs.
  • CD4+ and CD8+ variants enable the screening of therapeutic TCRs designed against MHCI- or MHCII-dependent antigens.

HiBiT-Based T Cell-Dependent Cytotoxicity (TDCC) Assay

  • The CD8 TDCC assay applies HiBiT complementation technology and can measure target cell-specific killing in mixed culture.
  • Primary CD8 T effector cells are prequalified in TDCC assay and can be used in thaw-and-use format without the need for cell culture.
  • The assay is homogenous, sensitive and fast.

Lumit™ Immunoassays for Cytokine Detection

  • The assay applies NanoBiT™ complementation technology and uses NanoBiT-labeled antibodies for the cytokine.
  • The assay is homogenous, fast and sensitive.
  • It shows linear correlation between assay signal and cytokine level.

Printed in USA. Revised 4/22